Brian Abrahams
Stock Analyst at RBC Capital
(2.41)
# 2,518
Out of 5,133 analysts
445
Total ratings
46.31%
Success rate
-0.7%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $103 | $74.13 | +38.95% | 2 | Dec 16, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $160 → $180 | $132.26 | +36.10% | 24 | Dec 8, 2025 | |
| SION Sionna Therapeutics | Downgrades: Underperform | $24 | $36.81 | -34.80% | 2 | Dec 1, 2025 | |
| PTCT PTC Therapeutics | Downgrades: Sector Perform | $82 → $91 | $75.40 | +20.69% | 23 | Dec 1, 2025 | |
| NMRA Neumora Therapeutics | Upgrades: Outperform | $4 → $7 | $2.14 | +227.10% | 7 | Dec 1, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $25 → $22 | $10.90 | +101.83% | 6 | Nov 21, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $19 → $18 | $15.39 | +16.96% | 5 | Nov 14, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $55 → $53 | $7.94 | +567.51% | 9 | Nov 13, 2025 | |
| ATYR aTyr Pharma | Maintains: Sector Perform | $1.5 → $1 | $0.71 | +41.62% | 2 | Nov 7, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $10 → $11 | $8.98 | +22.49% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.29 | +55.04% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $20 | $14.87 | +34.50% | 10 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $32 | $33.25 | -3.74% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $32 | $26.46 | +20.94% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $40.36 | +43.71% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $423 → $415 | $454.67 | -8.73% | 56 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $7.91 | +140.20% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $70 | $79.00 | -11.39% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $105 | $121.76 | -13.76% | 34 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $210 | $178.30 | +17.78% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $704 → $708 | $758.91 | -6.71% | 34 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $81 → $84 | $103.43 | -18.79% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $67 → $10 | $17.10 | -41.52% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $21.46 | +7.18% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $6.75 | +92.59% | 19 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $1.5 | $0.10 | +1,389.57% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $22.57 | +272.18% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $15.84 | +95.71% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $174.33 | -17.97% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $31.86 | +25.55% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $13.13 | +14.24% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.67 | +145.23% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $24.11 | - | 4 | Dec 4, 2017 |
Kymera Therapeutics
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $74.13
Upside: +38.95%
Neurocrine Biosciences
Dec 8, 2025
Maintains: Outperform
Price Target: $160 → $180
Current: $132.26
Upside: +36.10%
Sionna Therapeutics
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $36.81
Upside: -34.80%
PTC Therapeutics
Dec 1, 2025
Downgrades: Sector Perform
Price Target: $82 → $91
Current: $75.40
Upside: +20.69%
Neumora Therapeutics
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $2.14
Upside: +227.10%
Contineum Therapeutics
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $10.90
Upside: +101.83%
Aardvark Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $15.39
Upside: +16.96%
Corbus Pharmaceuticals Holdings
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $7.94
Upside: +567.51%
aTyr Pharma
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.71
Upside: +41.62%
Prothena Corporation
Nov 7, 2025
Maintains: Sector Perform
Price Target: $10 → $11
Current: $8.98
Upside: +22.49%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.29
Upside: +55.04%
Nov 7, 2025
Maintains: Outperform
Price Target: $21 → $20
Current: $14.87
Upside: +34.50%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $28 → $32
Current: $33.25
Upside: -3.74%
Nov 6, 2025
Maintains: Outperform
Price Target: $34 → $32
Current: $26.46
Upside: +20.94%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $40.36
Upside: +43.71%
Nov 4, 2025
Maintains: Sector Perform
Price Target: $423 → $415
Current: $454.67
Upside: -8.73%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $7.91
Upside: +140.20%
Nov 3, 2025
Maintains: Outperform
Price Target: $60 → $70
Current: $79.00
Upside: -11.39%
Oct 31, 2025
Maintains: Sector Perform
Price Target: $100 → $105
Current: $121.76
Upside: -13.76%
Oct 31, 2025
Maintains: Outperform
Price Target: $217 → $210
Current: $178.30
Upside: +17.78%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $704 → $708
Current: $758.91
Upside: -6.71%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $81 → $84
Current: $103.43
Upside: -18.79%
Sep 29, 2025
Downgrades: Sector Perform
Price Target: $67 → $10
Current: $17.10
Upside: -41.52%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $21.46
Upside: +7.18%
Jun 30, 2025
Reiterates: Outperform
Price Target: $13
Current: $6.75
Upside: +92.59%
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.10
Upside: +1,389.57%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $22.57
Upside: +272.18%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $15.84
Upside: +95.71%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $174.33
Upside: -17.97%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $31.86
Upside: +25.55%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.13
Upside: +14.24%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.67
Upside: +145.23%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $24.11
Upside: -